The Prostate Cancer Clinical Trials Working Group 3 (PCWG3) recommended recognising that a favourable effect on PSA may be delayed for ≥12 weeks after treatment initiation; hence, clinicians can ignore early rises (prior to 12 weeks) in determining the PSA response and plan to continue through early rises for a minimum of 12 weeks, unless other evidence of progression are present (82). The gene discussed is KLK3; the disease is prostate carcinoma.